The next 1-3 months is the biggest in the companies history and provides non dilutive funding for phase 2.
There are studies all the way from 2004 to 2023 that has supported the preclinical success NYR has already made in proving the drug works and beyond initial thought. We have a 2 in 1 phase 1 study for both TB and stroke. AGN does not have phase 1 TB study completed but NYR will have completed and ticked off for both TB and Stroke
Based off all the readings and research from 2004 until 2024 they all derisk the drug. For the drug it is and compared to its peers this is a 70-100 million dollar market cap right now with upside from there. To say this is a 11 million market cap and 10 million in funding is laughable
The next 1-3 months is the biggest in the companies history and...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.91M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 300 | 1 |
View Market Depth
| Last trade - 16.12pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.000 ( 2.82 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 6.9¢ | 6.9¢ | 15000 | ||
| Last updated 15.16pm 07/06/2024 ? | |||||
| NYR (ASX) Chart |
Day chart unavailable